|
|
|
|
|
|
|
|
|
|
The information
in this email is
intended only for
healthcare
professionals
in
Europe, the Middle East and Asia Pacific.
|
|
|
|
8.30am
|
Registration & Coffee
|
|
|
|
Jane Apperley, Chair
Department of Haematology and Professor of Haemato-oncology, Faculty of Medicine, Imperial College, London
|
|
|
|
9.00am
|
Session 1: Introduction to Immunomodulation
|
|
|
|
Improving immunologic outcomes of stem cell transplantation
Krishna Komanduri
Kalish Family Chair in Stem Cell Transplantation, Professor of Medicine, Microbiology & Immunology Director of the Adult Stem Cell Transplant Program, Associate Director for Clinical Innovation, at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami
|
|
|
|
9.30am
|
Session 2: The unmet need of acute GvHD
|
|
|
|
Making progress in the treatment of acute GvHD
Francis Ayuk
PD Dr. med, Clinic for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg
Role of intestinal microbiota in GvHD
Marcel van den Brink
Head, Division of Hematologic Oncology; Alan N. Houghton Chair, Memorial Sloan Kettering Cancer Center, New York. Professor of Medicine and Immunology, Weill Cornell Graduate School of Medical Sciences, New York
|
|
|
|
11.00am
|
Session 2: The unmet need of acute GvHD continued
|
|
|
|
Management of acute GvHD: strategies and clinical outcomes
Francesco Dazzi
Professor of Regenerative and Haematological Medicine, KHP Lead for Cellular Therapies, King’s College London, Visiting Professor at Imperial College, Rayne Institute, London
ECP in acute GvHD
Hildegard Greinix
Univ. Prof. Dr, Head of the Division of Haematology, Medical University of Graz, Graz
|
|
|
|
1.30pm
|
Session 3: The challenge of chronic GvHD
|
|
|
|
Identifying patients at risk of developing chronic GvHD and pre-emptive treatment
Andrea Bacigalupo
Professor of Haematology, Director of the Division of Haematology, Foundation Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome
What is the evidence base for our current chronic GvHD treatments?
Stephanie Lee
Member, Fred Hutchinson Cancer Research Center, Professor, University of Washington, Washington
ECP in chronic GvHD
Hildegard Greinix
Univ. Prof. Dr, Head of the Division of Haematology, Medical University of Graz, Graz
|
|
|
|
3.30pm
|
Session 4: UK Photopheresis Society
|
|
|
|
UK Photopheresis Society – Past, Present and Future
Fiona Dignan
Consultant Haemato-oncologist and Clinical Lead for Haematology, Manchester Royal Infirmary, Manchester
Development of UK Consensus Statement 2017
Arun Alfred
Consultant Haematologist, The Rotherham Foundation Trust, Rotherham
|
|
|
|
5.00pm
|
Reception at venue
|
|
|
|
This is a commercial programme run by Therakos (UK) Ltd. No registration fees.
|
|
|
|
|
|
|
|
